2023
Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice
SCHMID, Anna Marlene, Agnieszka RAZIM, Magdalena WYSMOLEK, Daniela KEREKES, Melissa HAUNSTETTER et. al.Základní údaje
Originální název
Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice
Autoři
SCHMID, Anna Marlene, Agnieszka RAZIM, Magdalena WYSMOLEK, Daniela KEREKES, Melissa HAUNSTETTER, Paul KOHL, Georgii BRAZHNIKOV, Nora GEISSLER, Michael THALER, Eliška KRČMÁŘOVÁ, Martin ŠINDELÁŘ (203 Česká republika, domácí), Tamara WEINMAYER, Jiří HRDÝ, Katy SCHMIDT, Peter NEJSUM, Bradley WHITEHEAD, Johan PALMFELDT, Stefan SCHILD, Aleksandra INIC-KANADA, Ursula WIEDERMANN a Irma SCHABUSSOVA (garant)
Vydání
Cell Communication and Signaling, BMC, 2023, 1478-811X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30102 Immunology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 8.400 v roce 2022
Kód RIV
RIV/00216224:14310/23:00133086
Organizační jednotka
Přírodovědecká fakulta
UT WoS
001095697400002
Klíčová slova anglicky
Allergic airway inflammation; Extracellular vesicles; Outer membrane vesicles; Microbiota and innate immunity; Nasal route of administration
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 18. 1. 2024 14:28, Mgr. Marie Šípková, DiS.
Anotace
V originále
Background E. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice. Methods EcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins and lipopolysaccharide; LPS), recognition by innate receptors (using transfected HEK293 cells) and immunomodulatory potential (in naive splenocytes and bone marrow-derived dendritic cells; BMDCs). Their allergy-preventive effect was investigated in a mouse model of ovalbumin-induced allergic airway inflammation. Results EcO83-OMVs are spherical nanoparticles with a size of about 110 nm. They contain LPS and protein cargo. We identified a total of 1120 proteins, 136 of which were enriched in OMVs compared to parent bacteria. Proteins from the flagellum dominated. OMVs activated the pattern recognition receptors TLR2/4/5 as well as NOD1 and NOD2. EcO83-OMVs induced the production of pro- and anti-inflammatory cytokines in splenocytes and BMDCs. Intranasal administration of EcO83-OMVs inhibited airway hyperresponsiveness, and decreased airway eosinophilia, Th2 cytokine production and mucus secretion. Conclusions We demonstrate for the first time that intranasally administered OMVs from probiotic G- bacteria have an anti-allergic effect. Our study highlights the advantages of OMVs as a safe platform for the prophylactic treatment of allergy.